Investigating the connection between diabetes drugs and weight loss in patients with type II diabetes mellitus: A prospective cohort study

IF 1.7 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Clinical Epidemiology and Global Health Pub Date : 2025-07-16 DOI:10.1016/j.cegh.2025.102135

P. Jagadeesh Chandra Prasad, Y. Lavanya, P. Nikhileswar Reddy, D. Shameera Banu, Rajavardhana Thamineni

{"title":"Investigating the connection between diabetes drugs and weight loss in patients with type II diabetes mellitus: A prospective cohort study","authors":"P. Jagadeesh Chandra Prasad, Y. Lavanya, P. Nikhileswar Reddy, D. Shameera Banu, Rajavardhana Thamineni","doi":"10.1016/j.cegh.2025.102135","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Diabetes mellitus is the most common of the endocrine disorders. It is a chronic condition, characterized by hyperglycemia and due to impaired insulin secretion with or without insulin resistance. American Diabetes Association (ADA) defines diabetes mellitus as a group of metabolic diseases characterized by inappropriate hyperglycemia resulting from defects in insulin secretion, insulin action, or both.</div></div><div><h3>Aim</h3><div>To investigate the correlation between different diabetic medications and weight fluctuations in individuals diagnosed with Type 2 Diabetes Mellitus (T2DM) through a prospective cohort study.</div></div><div><h3>Methods</h3><div>A Prospective Cohort study was conducted among type 2 diabetes mellitus patients. 410 volunteer patients were participated in our study. Out of them 18 members were excluded and 392 were included based on our study criteria.</div></div><div><h3>Results</h3><div>In this study we explored the relationship between Diabetic medications and type 2 diabetes mellitus patients. Our study shows that Metformin 500 mg and Voglibose 0.2 mg has significant association with GRBS Levels and Metformin 500 mg has significant association with weight loss. We also observed slight increase in weight in case of Glimepiride 1 mg & Glimepiride 2 mg but which is not clinically significant. Slight weight loss is observed in Sitagliptin 100 mg, Teneligliptin 20 mg, Vildagliptin 50 mg and Voglibose 0.2 mg but out of which those are not clinically significant.</div></div><div><h3>Conclusion</h3><div>Our findings underscore the importance of individualized medication management strategies tailored to optimize both glycaemic control and weight outcomes in type 2 diabetes mellitus management. Continued research in this area is essential to refine treatment guidelines and improve clinical outcomes for type 2 diabetes mellitus patients.</div></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":"35 ","pages":"Article 102135"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213398425002246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Diabetes mellitus is the most common of the endocrine disorders. It is a chronic condition, characterized by hyperglycemia and due to impaired insulin secretion with or without insulin resistance. American Diabetes Association (ADA) defines diabetes mellitus as a group of metabolic diseases characterized by inappropriate hyperglycemia resulting from defects in insulin secretion, insulin action, or both.

Aim

To investigate the correlation between different diabetic medications and weight fluctuations in individuals diagnosed with Type 2 Diabetes Mellitus (T2DM) through a prospective cohort study.

Methods

A Prospective Cohort study was conducted among type 2 diabetes mellitus patients. 410 volunteer patients were participated in our study. Out of them 18 members were excluded and 392 were included based on our study criteria.

Results

In this study we explored the relationship between Diabetic medications and type 2 diabetes mellitus patients. Our study shows that Metformin 500 mg and Voglibose 0.2 mg has significant association with GRBS Levels and Metformin 500 mg has significant association with weight loss. We also observed slight increase in weight in case of Glimepiride 1 mg & Glimepiride 2 mg but which is not clinically significant. Slight weight loss is observed in Sitagliptin 100 mg, Teneligliptin 20 mg, Vildagliptin 50 mg and Voglibose 0.2 mg but out of which those are not clinically significant.

Conclusion

Our findings underscore the importance of individualized medication management strategies tailored to optimize both glycaemic control and weight outcomes in type 2 diabetes mellitus management. Continued research in this area is essential to refine treatment guidelines and improve clinical outcomes for type 2 diabetes mellitus patients.

查看原文本刊更多论文

调查糖尿病药物与2型糖尿病患者体重减轻之间的关系：一项前瞻性队列研究

糖尿病是最常见的内分泌疾病。它是一种慢性疾病，以高血糖为特征，由于胰岛素分泌受损，伴有或不伴有胰岛素抵抗。美国糖尿病协会（ADA）将糖尿病定义为一组以胰岛素分泌缺陷、胰岛素作用缺陷或两者兼而有之导致的不适当高血糖为特征的代谢性疾病。目的通过前瞻性队列研究，探讨2型糖尿病（T2DM）患者不同糖尿病药物与体重波动的相关性。方法对2型糖尿病患者进行前瞻性队列研究。410名自愿患者参与了我们的研究。根据我们的研究标准，其中18人被排除，392人被纳入。结果本研究探讨了糖尿病药物与2型糖尿病的关系。我们的研究表明，二甲双胍500 mg和伏格糖0.2 mg与GRBS水平有显著相关性，二甲双胍500 mg与体重减轻有显著相关性。我们还观察到格列美脲1mg组体重略有增加；格列美脲2毫克，但没有临床意义。西格列汀100 mg、替尼格列汀20 mg、维格列汀50 mg和伏格列糖0.2 mg组均有轻微体重减轻，但没有临床意义。结论：我们的研究结果强调了个性化药物管理策略在2型糖尿病管理中优化血糖控制和体重结果的重要性。这一领域的持续研究对于完善治疗指南和改善2型糖尿病患者的临床结果至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.